ATR and non-small cell lung carcinoma: To test the hypothesis that ATR- or CHK1 inhibitors display particular efficacy in SCLC cells, compared to NSCLC cells, we next profiled the sensitivity of our cell line panel to the ATR inhibitor VE-822 and the CHK1 inhibitor PF-477736.